Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine

Tino F. Schwarz, Mariële Kocken, Tiina Petäjä, Mark H. Einstein, Marek Spaczynski, Jacqueline A. Louwers, Court Pedersen, Myron Levin, Toufik Zahaf, Sylviane Poncelet, Karin Hardt, Dominique Descamps, Gary Dubin

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

This pooled analysis of data from four Phase III clinical trials was undertaken to assess the correlation between levels of anti-human papillomavirus (HPV)-16/18 antibodies in serum and cervicovaginal secretions (CVS) in girls and women vaccinated with the HPV-16/18 AS 04-adjuvanted vaccine. Serum and CVS samples were collected from a subset of women aged 10-65 years (N = 350) at pre-specified time-points from 7 to 36 months post-vaccination. Anti-HPV-16/18 antibody levels in serum and CVS were measured by enzyme-linked immunosorbent assay. Pearson correlation coefficients between serum and CVS antibody levels, standardized for total immunoglobulin G, were calculated at each time-point in women with detectable antibodies in both serum and CVS. All subjects had seroconverted at Month 7 and remained seropositive through Month 36 for both antigens. Geometric mean titers of anti-HPV-16/18 antibodies in serum were substantially higher at all time-points than those in a control group of women who had cleared a natural HPV infection in another trial. In women with detectable antibodies in both serum and CVS, good correlation was seen between HPV-16/18 antibody levels at all time-points (Pearson correlation coefficient: 0.84-0.92 for HPV-16 and 0.90-0.91 for HPV-18). The strong correlation between levels of HPV-16/18 antibodies in serum and CVS up to 36 months post-vaccination in girls and women vaccinated with the HPV-16/18 AS 04-adjuvanted vaccine supports transudation of serum antibodies as the mechanism by which antibodies are introduced into CVS. These CVS antibodies may play a role in the protective efficacy of this vaccine.

Original languageEnglish (US)
Pages (from-to)1054-1061
Number of pages8
JournalHuman Vaccines
Volume6
Issue number12
DOIs
StatePublished - Dec 1 2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Immunology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Keywords

  • Cervicovaginal secretions
  • HPV
  • HPV-16/18 AS04-adjuvanted vaccine
  • Human papillomavirus
  • Prophylactic HPV vaccines

Fingerprint Dive into the research topics of 'Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine'. Together they form a unique fingerprint.

Cite this